Hope for Alzheimer’s patients as new drug donanemab slows cognitive decline 'by a third'

17 July 2023, 15:32 | Updated: 17 July 2023, 15:36

The drug could prove to bring new hope to Alzheimer's sufferers (file image)
The drug could prove to bring new hope to Alzheimer's sufferers (file image). Picture: Alamy

By Asher McShane

A new drug has been hailed as a "turning point in the fight against Alzheimer's" after it was found to slow the progression of the disease by up to a third.

Donanemab was found to slow "clinical decline" by up to 35%, meaning that people with disease could still go about performing day-to-day tasks including shopping, housekeeping, managing finances and taking medication.

Alzheimer's Research UK said that "we're entering a new era where Alzheimer's disease could become treatable".

And the Alzheimer's Society said that treatments like donanemab could one day mean that Alzheimer's could be likened to other long-term conditions such as asthma or diabetes.

The charity said that new treatments including donanemab - which works by removing a protein called amyloid that builds up in the brains of people with Alzheimer's - heralds a "new era" for Alzheimer's disease.

Read more: University is 'great but not the only way to succeed', PM tells LBC as he outlines crackdown on ‘Mickey Mouse’ degrees

Read more: Daniel Morgan's family to receive £2m over Met's murder probe failings in one of British policing's biggest ever payouts

It comes as scientists published the final results of the trial - known as TRAILBLAZER ALZ-2 - examining the safety and efficacy of the drug, manufactured by Eli Lilly and Company.

Researchers examined almost 1,800 people with early-stage Alzheimer's.

Half of them received a monthly infusion of donanemab and the other half were given a dummy drug, also known as a placebo, over 18 months.

The study, published in the Journal of the American Medical Association and presented to the Alzheimer's Association International Conference in Amsterdam, concluded that after 76 weeks of treatment, donanemab was able to slow clinical decline by 35.1% in people with early Alzheimer's whose brain scans showed low or medium levels of a protein called tau.

When the results were combined for people who had different levels of this protein, there was a 22.3% slowing in disease progression.

But researchers did find that among a small number of people in the study there were some serious side effects such as brain swelling.

Meanwhile three deaths in the donanemab group and one in the placebo group were considered "treatment related".

The results come after another drug - lecanemab - was found to reduce memory decline among patients with early-stage disease.

Commenting on the results, Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: "This is truly a turning point in the fight against Alzheimer's and science is proving that it is possible to slow down the disease.

"Treatments like donanemab are the first steps towards a future where Alzheimer's disease could be considered a long-term condition alongside diabetes or asthma - people may have to live with it, but they could have treatments that allow them to effectively manage their symptoms and continue to live fulfilled lives.

"Today's full results support what we heard about donanemab back in May, that the drug is able to slow down the progression of Alzheimer's disease by more than 20%.

"This study adds to the growing evidence that treating people as early as possible may be more beneficial, with the effects of donanemab greater in people who were at an earlier stage of the disease.

"Diagnosis will be key to the access of any new treatments.

"We can't have a situation where treatments are approved for use in the UK but people aren't diagnosed early or accurately enough to be eligible.

"We need early, and accurate, diagnoses available for everyone and the NHS ready to roll out treatments such as donanemab and lecanemab if and when they are approved in the UK."

He added: "It's also important to note that side effects did occur, although serious side effects only occurred in 1.6% of people receiving the drug.

"Regulators will need to balance these side effects against the benefits of the drug.

"We should also note that the majority of people who took part in this trial were white - it's crucial that in future trials we see more diversity to prove that new drug treatments have similar effects for everyone living with Alzheimer's disease.

"Just as we've seen a transformation in cancer treatment in recent decades, we're really hopeful we're on the same path for dementia."

Sir John Hardy, professor of neuroscience and group leader at the UK Dementia Research Institute, UCL, added: "The successful outcome of the Eli Lilly's anti-amyloid antibody donanemab is great news for Alzheimer's disease and confirms the positive and similar outcome for Eisai's lecanemab trial late last year.

"The results are very similar, and that in itself is reassuring.

"Disease progression is slowed about 30%, but it too has occasionally serious complications which require monitoring.

"Scientists now need to work to understand what we need to do to stop the disease rather than just slow it, but the major immediate task will be to organise NHS Alzheimer provision to be able to use these therapies."

More Latest News

See more More Latest News

c

New EPC rules for landlords could lead to higher rents and fewer homes

PM holds 'crisis summit' after Bank of England warning over 'Stagflation'

'Either be disruptors or disrupted': Starmer tells ministers at start of 'crisis summit' after 'Stagflation' warning

Exclusive
Marcelle King

'My face was swelling up like Frankenstein's Monster': LBC uncovers scores of illegal botox products being sold online

President Trump Hosts Japan's Prime Minister Shigeru Ishiba At The White House

Donald Trump slams brakes on some China tariffs in third trade war U-turn

2020 Vanity Fair Oscar Party Hosted By Radhika Jones - Roaming Arrivals

Calls for Kanye West to be removed from X after 'antisemitic rampage' online

Netlifx has hiked its subscription prices without adverts by £2, or 18%, to £12.99 a month for British users.

Netflix hikes prices for Brits after hitting record subscription figures

EL SALVADOR-RELIGION-WELBY

Justin Welby to live at Lambeth Palace despite quitting as archbishop after report into Church safeguarding failures

Retired PC Tim Bradshaw (left) and Andrew Newman, deputy chair of Sussex Police Federation, outside Portsmouth Crown Court

Retired police officer found not guilty after knocking two men off electric motorbike in order to 'protect life'

Detective Sergeant Richard Mills, aged 42, of Rochdale was sentenced to 18 months in prison at Liverpool Crown Court

Police detective jailed for 18 months after two sexual assaults on colleagues in workplace

A music teacher who appeared on a hit Channel 4 show has been accused of sexual assault and making indecent images of children.

Music teacher who appeared in hit Channel 4 show charged with making indecent images of children

Exclusive
A former prisoner who was pregnant while behind bars has called for childbearing women to get more support from the justice system.

‘I cried myself to sleep, covered in blood’: Former prisoner who was pregnant while jailed calls for justice system overhaul

Six-month old Sophia Kelemen was killed by a driverless car in a horror accident on January 2.

Baby girl dies in horror accident after driverless car smashes into pram on family holiday

Mohamed Al-Fayed's brother has denied sexual assault allegations brought forward by three former Harrods employees.

Mohamed Al Fayed's brother 'unequivocally' denies sexual assault allegations by three former Harrods employees

Kanye West, left, and Bianca Censori arrive at the 67th annual Grammy Awards on Sunday, Feb. 2, 2025, in Los Angeles. (Photo by Jordan Strauss/Invision/AP)

Kanye West declares he’s a ‘Nazi,’ ‘loves Hitler’ and that he has ‘dominion’ over Bianca Censori in vile rant

A British man found dead with his wife inside their isolated French villa

British couple found dead in French villa named as fears former organised crime financial investigator was 'murdered'

TV chef Gino D'Acampo’s ITV shows have been pulled from schedules

Gino D’Acampo TV shows pulled from schedules amid investigation into ‘sexually inappropriate’ comments